| Market Capitalization | ₹1,06,453.7 CrLarge Cap |
|---|---|
| Revenue TTM | ₹33,700.2 CrOperating Income |
| Relative Strength Index | 45.75Neutral Zone |
| Price to Earnings | 25.37TTM Ratio |
Key highlights
- First-to-market launch of Bosutinib Tablets 400mg in the United States market
- Eligible for 180 days of generic drug exclusivity for the 400mg strength
- Targeting a brand market with approximately $253.8 million in annual U.S. sales
- Collaboration with MSN Laboratories for development and manufacturing processes
- Dr. Reddy's maintains exclusive marketing rights for the product in the U.S.
The Product — What It Is
Bosutinib is a potent Tyrosine Kinase Inhibitor (TKI) used primarily in oncology for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. As a generic equivalent of Bosulif, this 400mg tablet formulation offers a high-quality, more affordable therapeutic option for patients requiring complex cancer treatments. The product's first-to-file status in the United States provides a competitive advantage by allowing a period of market exclusivity, which is critical for maximizing penetration in the highly regulated U.S.
pharmaceutical landscape. This launch specifically addresses a high-priority therapy area where access and affordability are primary concerns for healthcare providers.
Commercial Opportunity
- Brand sales for Bosulif 400mg reached approximately $253.8 million in the U.S. for the 12 months ended April 2026
- The 180-day exclusivity period allows for a significant lead time before other generic competitors can enter the 400mg market
- MSN Laboratories handles the manufacturing and development, leveraging their Hyderabad and New Jersey USFDA-approved facilities
- Dr. Reddy's exclusive marketing rights ensure direct control over commercial distribution and pricing strategies in North America
- Market entry aligns with the company's focus on broadening access to high-priority oncology therapies
Strategic Fit and Business Overview
This launch reinforces Dr. Reddy's commitment to the oncology segment, one of its core therapeutic areas alongside gastrointestinal and cardiovascular medicine. By partnering with MSN Laboratories, Dr.
Reddy's utilizes a capital-light model where it focuses on its marketing and distribution strengths while benefiting from MSN's specialized manufacturing capabilities. The company maintains a global presence across major markets including India, Russia, and Europe. Financially, while the company reported a Net Profit of ₹4,196 crore TTM, this launch serves as a potential growth driver to offset pricing pressures in other generic categories, supporting the long-term goal of sustainable margin expansion.
Management Perspective
This launch highlights our commitment to leading with timely market entry for high-priority therapies while broadening access for both patients and healthcare providers.
“The successful development and commercialization of Bosutinib Tablets demonstrates MSN’s strong scientific, regulatory, and manufacturing capabilities in complex oncology products.”
| Share price | ₹1275.4 |
|---|---|
| Market capitalisation | ₹1.06L Cr |
| Revenue (annual) | ₹33,700.20 Cr |
| Net profit (annual) | ₹4,196.00 Cr |
| Revenue (latest quarter) | ₹7,546.40 Cr-13.79% vs previous quarter |
| Net profit (latest quarter) | ₹220.90 Cr-81.74% vs previous quarter |
| P/E (TTM) | 25.37×Sector 40.7× |
| Promoter holding | 26.63%-0.01% QoQ |
| FII holding | 21.14%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Dr. Reddy's Laboratories announcing the first-to-market launch of Bosutinib Tablets in the United States. Market figures from a third-party data provider.
